Additional clinical trials with CCR5+ metastatic cancer patients are currently underway to evaluate the combination of either a CCR5 antagonist with a biologic, or of leronlimab with a conventional chemotherapeutic agent [162]. The gene discussed is CCR5; the disease is metastatic malignant neoplasm.